Literature DB >> 23996327

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).

Anthea Craven1, Joanna Robson2, Cristina Ponte3,4, Peter C Grayson5, Ravi Suppiah6, Andrew Judge2, Richard Watts7, Peter A Merkel8, Raashid A Luqmani2.   

Abstract

The systemic vasculitides are a group of uncommon diseases characterized by blood vessel inflammation. There are currently no diagnostic criteria for the primary systemic vasculitides and physicians must rely on experience and disease definitions. The absence of validated criteria can result in delays in making the correct diagnosis and starting appropriate therapy. With the increased understanding of the pathophysiology of vasculitis and newer diagnostic tests in widespread clinical use, it is an appropriate time for classification criteria for primary vasculitis to be revised. The Diagnostic and Classification Criteria for Vasculitis (DCVAS) study is a multinational observational study designed to develop and validate diagnostic criteria and to improve and validate classification criteria for primary systemic vasculitis. The analytic approach will be based on the traditional approach of vessel size for classification of vasculitis but will also incorporate detailed clinical data, evaluation of anti-neutrophil cytoplasm antibody diagnostic testing, biopsy and imaging data. The study is following the guidelines for the development of classification criteria established by the American College of Rheumatology and the European League against Rheumatism. The study will incorporate the use of pre-defined cases of each condition to reduce the inherent circularity when developing new classification criteria and will explore alternative approaches to deriving reference standards by creating data-driven classification algorithms. We anticipate recruiting >2,000 patients with primary systemic vasculitis and 1,500 patients with autoimmune diseases and other conditions that mimic vasculitis. As of June 2013, >100 medical centers across 31 countries in Asia, Australasia, Europe, North America, and South America were contributing data to the study. The DCVAS study provides a unique opportunity to increase generalizability and collate a large dataset on the occurrence, presentation, and outcome of vasculitis in different populations.

Entities:  

Mesh:

Year:  2013        PMID: 23996327     DOI: 10.1007/s10157-013-0854-0

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  4 in total

1.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods.

Authors:  D A Bloch; B A Michel; G G Hunder; D J McShane; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; J F Fries; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

2.  Development of classification and response criteria for rheumatic diseases.

Authors:  Jasvinder A Singh; Daniel H Solomon; Maxime Dougados; David Felson; Gillian Hawker; Patricia Katz; Hal Paulus; Carol Wallace
Journal:  Arthritis Rheum       Date:  2006-06-15

3.  Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K.

Authors:  Shouichi Fujimoto; Richard A Watts; Shigeto Kobayashi; Kazuo Suzuki; David R W Jayne; David G I Scott; Hiroshi Hashimoto; Hiroyuki Nunoi
Journal:  Rheumatology (Oxford)       Date:  2011-07-28       Impact factor: 7.580

4.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
  4 in total
  44 in total

Review 1.  Classification of ANCA-associated vasculitis.

Authors:  Irfan Khan; Richard A Watts
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

2.  Important role of translational science in rare disease innovation, discovery, and drug development.

Authors:  Anne R Pariser; William A Gahl
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

Review 3.  Key advances in the clinical approach to ANCA-associated vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

4.  Treating elderly patients with ANCA-associated vasculitis.

Authors:  J Ashley Jefferson
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-22       Impact factor: 8.237

Review 5.  Updates in ANCA-associated vasculitis.

Authors:  Christian Pagnoux
Journal:  Eur J Rheumatol       Date:  2016-01-29

Review 6.  Critical appraisal of classification criteria for vasculitides.

Authors:  Luis Felipe Flores-Suárez; Felipe de J Contreras-Rodríguez
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

7.  [Update: polyarteritis nodosa].

Authors:  Jan H Schirmer; Frank Moosig
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

Review 8.  Vasculitis: do we know more to classify better?

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

Review 9.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

10.  An update on the general management approach to common vasculitides.

Authors:  Mooikhin Hng; Sizheng S Zhao; Robert J Moots
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.